Patents Examined by Stacy B. Chen
-
Patent number: 11872277Abstract: The present invention provides novel engineered Ebolavirus GP proteins and polypeptides, scaffolded vaccine compositions that display the engineered proteins, and polynucleotides encoding the engineered proteins and scaffolded vaccine compositions. The invention also provides methods of using such engineered Ebolavirus GP proteins and vaccine compositions in various therapeutic applications, e.g., for preventing or treating Ebolavirus infections.Type: GrantFiled: April 7, 2022Date of Patent: January 16, 2024Assignee: The Scripps Research InstituteInventors: Linling He, Jiang Zhu, Anshul Chaudhary, Ian Wilson
-
Patent number: 11844832Abstract: Provided are methods for rapidly inactivating a pathogen, or for producing a vaccine composition containing an inactivated noninfectious pathogen having retained antigenicity and/or immunogenicity, comprising exposing the pathogen to a chemical inactivating agent (e.g., one or more chemical oxidizing, alkylating or crosslinking agents) in the presence of inorganic polyatomic oxyanions in an amount and for a time sufficient to render the pathogen noninfectious while enhancing retention of pathogen antigenicity and/or immunogenicity relative to that retained by contacting the pathogen with the chemical inactivating agent alone. The methods are broadly applicable to pathogens having RNA or DNA genomes (e.g., including viruses, bacteria, fungi, and parasites).Type: GrantFiled: August 14, 2020Date of Patent: December 19, 2023Assignee: Najit Technologies, Inc.Inventors: Ian J. Amanna, Elizabeth A. Poore
-
Patent number: 11845777Abstract: The present invention provides redesigned soluble coronavirus S protein derived immunogens that are stabilized via specific modifications in the wildtype soluble S sequences. Also provided in the invention are nanoparticle vaccines that contain the redesigned soluble S immunogens displayed on self-assembling nanoparticles. Polynucleotide sequences encoding the redesigned immunogens and the nanoparticle vaccines are also provided in the invention. The invention further provides methods of using the vaccine compositions in various therapeutic applications, e.g., for preventing or treating coronaviral infections.Type: GrantFiled: November 3, 2020Date of Patent: December 19, 2023Assignee: The Scripps Research InstituteInventors: Linling He, Jiang Zhu, Ian A. Wilson
-
Patent number: 11827675Abstract: The present invention includes nucleic acids, proteins, Chikungunya virus (CHIKV) Virus Like Particles (VLP), and methods of making a Chikungunya virus (CHIKV) Virus Like Particles (VLP) comprising: inserting one or more nucleic acids into a lentiviral backbone, wherein the nucleic acid encodes one or more Chikungunya virus (CHIKV) proteins; transfecting the one or more nucleic acids into the lentiviral backbone into a cell line; culturing the transfected cell line under conditions in which the Chikungunya virus (CHIKV) Virus Like Particles (VLP) are released from the cell line; and isolating the Chikungunya virus (CHIKV) Virus Like Particles (VLP) from a culture supernatant.Type: GrantFiled: September 26, 2019Date of Patent: November 28, 2023Assignee: Texas Tech University SystemInventors: Himanshu Garg, Anjali Joshi
-
Patent number: 11807849Abstract: The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease and Gaucher disease. In some embodiments, the disclosure provides expression constructs comprising a transgene encoding one or more inhibitory nucleic acids targeting SCNA or a portion thereof, TMEM106B or a portion thereof, or any combination of the foregoing. In some embodiments, the disclosure provides methods of Parkinson's disease by administering such expression constructs to a subject in need thereof.Type: GrantFiled: October 3, 2018Date of Patent: November 7, 2023Assignee: Prevail Therapeutics, Inc.Inventors: Asa Abeliovich, Laura Heckman, Herve Rhinn
-
Patent number: 11802146Abstract: This disclosure relates to compositions and methods for treating and preventing chikungunya virus infection by delivering polynucleotides encoding anti-chikungunya virus antibodies to a subject. Compositions and treatments provided herein include one or more polynucleotides having an open reading frame encoding an anti-chikungunya virus antibody heavy chain or fragment thereof and/or an anti-chikungunya virus antibody light chain or fragment thereof. Methods for preparing and using such treatments are also provided.Type: GrantFiled: January 4, 2019Date of Patent: October 31, 2023Assignees: ModernaTX, Inc., Vanderbilt UniversityInventors: Sunny Himansu, James E. Crowe, Jr., Giuseppe Ciaramella
-
Patent number: 11786589Abstract: A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine.Type: GrantFiled: June 16, 2021Date of Patent: October 17, 2023Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Baoming Jiang, Roger I. Glass, Yuhuan Wang, Jon Gentsch
-
Patent number: 11786591Abstract: Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.Type: GrantFiled: May 28, 2021Date of Patent: October 17, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Institute for Research in BiomedicineInventors: Peter Kwong, Michael Gordon Joyce, Baoshan Zhang, Yongping Yang, Peter Collins, Ursula Buchholz, Davide Corti, Antonio Lanzavecchia, Guillaume Stewart-Jones
-
Patent number: 11779640Abstract: The present invention relates to a lentiviral vector-based Japanese encephalitis (JE) immunogenic composition. The present invention is directed to a recombinant lentiviral vector expressing the precursor of membrane (prM) and the envelope (E) protein, in particular glycoprotein of a Japanese encephalitis virus (JEV) or immunogenic fragments thereof. The present invention also provides cells expressing the lentiviral vector, uses and methods to prevent a JEV infection in a mammalian host, especially in a human or an animal host, in particular a pig or a piglet, preferably a domestic pig or a domestic piglet.Type: GrantFiled: February 19, 2020Date of Patent: October 10, 2023Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Pierre Charneau, Philippe Despres, Melissanne De Wispelaere, Philippe Souque, Marie-Pascale Frenkiel
-
Patent number: 11767540Abstract: In a first aspect, the present invention relates to a mutated adeno-associated virus (AAV) capsid protein or fragment thereof wherein a substitution of a wild type non-cysteine amino acid into a cysteine is present whereby the wild type non-cysteine amino acid is exposed on the outer surface of the capsid of an AAV particle. In a further aspect, a mutated AAV particle comprising the AAV capsid protein or fragment thereof according to the present invention is provided. In addition, a nucleic acid encoding the AAV capsid protein according to the present invention is identified together with a corresponding nucleic acid vector, in particular, a plasmid or a gene string. In addition, a host cell containing the nucleic acid vector or the nucleic acid according to the present invention as well as a composition comprising at least an infectious (transducing) AAV particle containing a mutated AAV capsid protein as defined herein together with a non-infectious AAV particle containing a mutated AAV capsid protein as e.Type: GrantFiled: September 28, 2018Date of Patent: September 26, 2023Assignee: FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEW ANDTEN FORSCHUNG E.V.Inventors: Hildegard Büning, Anke Huber, Luca Perabo
-
Patent number: 11753627Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.Type: GrantFiled: September 1, 2020Date of Patent: September 12, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph Blaney, Kathryn Hanley, Ching-Juh Lai
-
Patent number: 11738079Abstract: The present disclosure relates to vaccines and methods for the prevention and treatment of Zika virus infection. Particularly, the present disclosure relates to viral and DNA vaccine vectors which includes or encode for secreted immunogenic peptides of NS1 that eliciting a protective immune response and prevent Zika virus infection of a subject.Type: GrantFiled: July 23, 2019Date of Patent: August 29, 2023Inventors: Eric James Gowans, Branka Grubor-Bauk, Danushka Wijesundara
-
Patent number: 11739348Abstract: Embodiments disclosed herein provide compositions, methods, and uses for recombinant vectors encoding Zika virus (ZIKV) protein subunits, and immunogenic compositions thereof. Certain embodiments provide recombinant vectors encoding ZIKV nonstructural protein 1 (NS 1), and optionally, ZIKV envelope (E) protein and premembrane (prM) protein. Other embodiments provide expression cassettes comprising a promoter operably linked to a polynucleotide that encodes the ZIKV NS 1 protein, and optionally ZIKV E and prM proteins. In some embodiments, the disclosed expression cassettes can be incorporated into a vector to produce a recombinant vector. Also provided are immunogenic compositions comprising one or more recombinant vectors described herein, and methods for inducing an immune response against ZIKV in a subject comprising administering to the subject an immunologically effective dose of an immunogenic composition of the present disclosure.Type: GrantFiled: November 9, 2018Date of Patent: August 29, 2023Assignees: The Research Institute at Nationwide Children's Hospital, Ohio State Innovation FoundationInventors: Mark Peeples, Jianrong Li, Prosper N. Boyaka, Anzhong Li, Mijia Lu, Yuanmei Ma
-
Patent number: 11730804Abstract: The present disclosure relates generally to the field of molecular virology, and particularly relates to nucleic acid molecules encoding a modified alphavirus virus viral genome or self-replicating RNA (srRNA) construct, recombinant cells and pharmaceutical compositions containing the same, as well as the use of such nucleic acid molecules, recombinant cells and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting an immune response in a subject in need thereof, as well as methods for preventing and/or treating rabies virus infection.Type: GrantFiled: April 13, 2022Date of Patent: August 22, 2023Assignee: Replicate Bioscience, Inc.Inventors: Nathaniel Stephen Wang, Shigeki Joseph Miyake-Stoner, Parinaz Aliahmad, Andrew Geall
-
Patent number: 11713469Abstract: Provided herein are adenoviral vectors comprising nucleotide sequences encoding a Zika virus M and Env antigen, wherein the nucleotide sequence encoding the Zika virus M and Env antigen is operably linked to a cytomegalovirus (CMV) promoter comprising at least one tetracycline operator (TetO) motif. Also provided herein are pharmaceutical compositions comprising the adenoviral vectors, methods of producing the adenoviral vectors, methods of preventing Zika virus or the progression of Zika virus in a subject in need thereof, and kits comprising the adenoviral vectors and host cells.Type: GrantFiled: July 19, 2019Date of Patent: August 1, 2023Assignee: Janssen Vaccines & Prevention B.V.Inventor: Taco Gilles Uil
-
Patent number: 11707504Abstract: Fusion peptide inhibitors of human coronavirus 229E are provided. The fusion peptide inhibitors of HCoV-229E include peptide #1 (SEQ ID NO: 1: SLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKEL), peptide #4 (SEQ ID NO: 2: SLTQINWTLLDLTYEMESLQQVVKALNESYIDLKEL), and peptide #11 (SEQ ID NO: 11: SLTQINTTLLDLEYEMRSLEEVVKKLNESYIDLKEL. The fusion peptide inhibitors of HCoV-229E may be administered to a subject in need thereof to inhibit or prevent HCoV-229E cellular entry or infection with HCoV-229E. The fusion peptide inhibitors of HCoV-229E may also be used in HCoV-229E inhibition assays.Type: GrantFiled: June 27, 2022Date of Patent: July 25, 2023Assignee: KING FAISAL UNIVERSITYInventors: Mahmoud Kandeel Elsayed, Abdullah I. Al-Mubarak
-
Patent number: 11709116Abstract: A kit and method for flow cytometry include a liquid dye concentrate for fluorescent staining of virus-size particles with a plurality of fluorogenic dyes in a liquid medium. The liquid dye concentrate includes a plurality of fluorogenic dyes and one or both of (i) the liquid medium comprising a liquid mixture including water and liquid phase organic material and (ii) disaccharide dissolved in the liquid medium.Type: GrantFiled: February 4, 2020Date of Patent: July 25, 2023Assignee: SARTORIUS BIOANALYTICAL INSTRUMENTS, INC.Inventors: Rebecca K. Montange, Jeffrey W. Steaffens
-
Patent number: 11707516Abstract: Provided is a method for producing an artificial recombinant virus of the family Reoviridae, the method comprising the steps of: (1) introducing a FAST protein expression vector and/or a capping enzyme expression vector into host cells; (2) introducing a vector containing expression cassettes for individual RNA genome segments of a virus or introducing a set of single-stranded RNA transcripts from the expression cassettes into host cells; and (3) culturing the host cells. The method of the present invention allows more efficient production of an artificial recombinant virus of the family Reoviridae as compared with conventional methods and allows artificial recombinant rotavirus production without using a helper virus.Type: GrantFiled: September 26, 2017Date of Patent: July 25, 2023Assignee: Osaka UniversityInventors: Takeshi Kobayashi, Yuta Kanai
-
Patent number: 11701423Abstract: In one aspect, the present disclosure is directed to a method for preventing or treating a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a hyperimmunized egg product obtained from an egg-producing animal, thereby preventing or treating coronavirus infection in the subject, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more antibodies to the coronavirus.Type: GrantFiled: March 11, 2022Date of Patent: July 18, 2023Assignee: LAY SCIENCES, INC.Inventors: Subramanian V. Iyer, Satishchandran Chandrasekhar, Uday Saxena, Gopi Kadiyala
-
Patent number: 11702453Abstract: The disclosure provides materials in the form of flavivirus variants that each encode a Non-Structural Protein-1 (NS1) variant, wherein the coding region is a chimera of at least two different NS1 coding regions, or wherein the coding region has at least one mutation in a codon of a canonical Asn-Xxx-Ser/Thr N-linked glycosylation site, wherein Asn is asparagine, Xxx is any amino acid, and Ser/Thr is either serine or threonine, or wherein the coding region is both a chimera and has at least one mutation in a codon of a canonical N-liked glycosylation site, wherein Asn is asparagine, Xxx is any amino acid, and Ser/Thr is either serine or threonine. The disclosure also provides methods of using such flavivirus variants to inhibit the transmission of infectious flavivirus.Type: GrantFiled: August 20, 2019Date of Patent: July 18, 2023Assignee: REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Andrew Tai, David Lin